Clinical Trial - Veterinarians CBD Knowledge

Us Veterinarians Knowledge, Experience, and Perceptions Regarding the Use of Cannabidiol for Canine Medical Conditions. Published Jan 2019

1 - 2130 participants completed an anonymous online survey. It was created in collaboration with VIN (Veterinary Information Network-an online veterinary community). To evaluate views regarding marijuana and CBD/hemp products.

2 - Any participant who was not in clinical practice (n=26) or did not treat dogs (n=52) were eliminated from the survey.

3 - Participants were asked how often did their clients enquired about CBD products. Totals: rarely (29.2%) monthly (26.4%) never (8%) and daily (7.4%). Clients visiting veterinarians who worked in states that have legalized recreational marijuana were more likely to ask about CBD for their pet as noted in Table 2 chart in the trial.

4 - Participants were asked to identify the specific conditions or diseases for which clients were seeking information. More than one response was allowed. The 4 most common topics were for pain management, anxiety, seizures and storm/fireworks.

5 - Participants were asked about the endorsement of CBD products. Totals: never (44%) rarely (28.8%) sometimes (18.9%) frequently (8%). When asked what was the reason for not advising their clients only half answered the question. Totals: Not enough knowledge about CBD (68.1%) more research is needed (59.57%) it is illegal (48.8%) concerns about toxicity (19.7%)

6 - Perceived impact of CBD products for common canine medical conditions: Decrease’s pain for acute pain - somewhat helpful. Decrease’s pain for chronic pain - somewhat helpful. Reduces anxiety -somewhat helpful. Decrease’s seizures - somewhat helpful. Decrease’s pain for chronic pain – very helpful.

7 - Perception of state organizations’ provision of ‘sufficient guidance’ regarding the use of CBD. Strongly disagree (22%) Disagree (31%) Neutral (24%) Agree (17.3%) Strongly agree (4%)

8 - Overall all participants strongly agree that more toxicity research needs to be done.

9 - 83% Strongly disagree or disagree that CBD should remain a Schedule 1 drug as defined by the DEA. (CBD was removed from the Schedule 1 drug category in January 2020)

10 - 84% Strongly disagree or disagree that Hemp/CBD products for animals should remain illegal at the Federal level.

To view clinical trial: ncbi.nlm.nih.gov/pmc/articles/PMC6338022/

Clinical Trial Baylor Osteoartritis - 2020

Randomized, double-blind, placebo-controlled study of daily cannabidiol for the treatment of canine osteoarthritis. April 2020

1-The cannabidiol used was provided by MedterraCBD (Irvine, CA), free from THC and the Hemp used was farmed under the strict guidelines of the Department of Agriculture Industrial Hemp pilot program. The CBD used was a 99.99% pure isolate combined with fractionated coconut oil.

2- To increase the effectiveness of the CBD isolate, it was packaged within liposomes, a vehicle delivery system previously shown to improve the uptake of other hydrophobic compounds.

3- Canine veterinary studies were performed with oversight at Baylor College of Medicine. The study population consisted of client owned dogs presented to the Sunset Animal Hospital (Houston, Tx) for evaluation and treatment due to osteoarthritis.

4- Dogs were given either a 20 mg CBD dose, a 50 mg CBD dose or placebo and were evaluated by the owners and the veterinarians.

5- Results were that short-term administration of 50 mg CBD to domestic canines diagnosed with osteoarthritis demonstrated robust and quantifiable anti-inflammatory properties in experimental systems.

To few the clinical trial: www.reserchgate/publication/34098209

Update on Cannabis-derived and Cannabis-related Products

1. The Farm Bill also removed tetrahydrocannabinols included in ‘hemp’ from Schedule I under the CSA. It did not, however, change the FDA’s authority to regulate drugs and food under the federal Food, Drug, and Cosmetic Act (FDCA)

2. The FDA has commented on CBD products marketed as dietary supplements stating that, “Some of the products are marketed as dietary supplements. However, CBD products cannot be dietary supplements because they do not meet the definition of a dietary supplement under the FDCA.”

3. In determining whether something is a drug, ‘intent to use’ is very important and is defined by the FDA. The FDA determines a product's ‘objective intent’ by what appears in labeling claims, advertising matter, and oral or written statements by manufacturers, sponsors, or their representatives.

4. To our knowledge, there are no long-term safety data available for the use of CBD in companion animals.

5. Results of a very small-scale study (8 dogs, 8 cats; no animals used as controls) focusing on pharmacokinetics an d safety were recently (October 19, 2019) published in Animals. The study included a preliminary safety and adverse effect assessment for the dogs and cats given CBD at a dose of 2 mg/kg for 12 weeks. Serum chemistry and CBC results showed no clinically significant alterations or did physical examinations.

Reference: https://www.avma.org/sites/default/files/2020-01/2019_12_AVMA-Update-Cannabis-Derived-and-Cannabis-Related-Products.pdf